ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Wyngaarden Suspends NIH Funds for Pennsylvania Head Injury Center Over Animal Care Problems

July 26, 1985

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

December 31, 2010

ACCC Considers Role Of Allied Personnel, Funds, Center Components

February 13, 1976

In Brief: McDonnell Foundation Awards Four Fellowships; UCLA’s Kenneth Shine Is Next IOM President

January 10, 1992

Yarbro-Chabner Debate Continues

April 29, 1983

Randomization With Options Stimulates Sedmental Accrual

February 22, 1980